Science 37 and Xperiome Partner to Speed Rare Disease Studies for Patients and Providers

Rare Daily Staff

Science 37, a leader in decentralized clinical trials, has partnered with rare disease healthtech company Xperiome to increase the efficiency and speed of rare disease clinical trials.

Science 37 will leverage Xperiome’s insights from its Raremark knowledge bank, including a specialized matching engine to connect research-ready members to clinical and real-world study opportunities.

Clinical studies for rare diseases have always presented challenges. From investigator training to data collection, researching rare disease is mired with condition-specific obstacles that slow development and place an enormous burden on patients wanting to participate in a potentially life-saving clinical trial. By leveraging Xperiome’s rare disease patient communities—combined with Science 37’s Decentralized Clinical Trial Operating System—the company said sponsors can more effectively run a decentralized clinical trial to speed the development of therapies.

“At Science 37, our purpose of enabling universal access for clinical research is predicated on making it easier for patients to participate,” said David Coman, CEO of Science 37. “The burden is typically doubled in rare disease studies, as it’s usually not just the patient alone traveling to and from a research site. By partnering with Xperiome and their rare disease communities, we can help design more patient-centric decentralized studies, reduce patient burden, and provide more opportunity to participate, which ultimately accelerates the development of treatments that impact patients’ lives.”

Photo: David Coman, CEO of Science 37